DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All

DexCom, Inc. (NASDAQ:DXCM) is among the Best Healthcare Stocks.

On June 23, DexCom, Inc. (NASDAQ:DXCM) announced that the FDA cleared growing use of its Stelo Glucose Biosensor beyond adults for children ages 2 and older who do not use insulin.

President and CEO Jake Leach said, "Glucose matters for everyone." The company plans to broaden access to glucose biosensing while making preventive, customized care more accessible through a redesigned Stelo app.

DexCom, Inc. (NASDAQ:DXCM) said the updated app will begin rolling out in America in July for Apple iPhone and Android users, providing easier-to-understand glucose insights linked to food, activity, sleep, and stress.

The corporation also said it plans to launch Stelo in the United Kingdom, Australia, New Zealand, and South Korea beginning later this year and continuing into 2027.

The medical device firm said that Type 2 diabetes and related health issues are becoming more common in young people, so children and their parents who do not use insulin can now get blood sugar tracking data without needing a doctor's prescription.

DexCom, Inc. is a medical device company that works in the design, development, and marketing of glu

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/dexcom-inc-dxcm-further-advances-195820163.html)